Asset Publisher

ph-1049

Insomnia Agents Quantity Limit Program Summary

Policy Number: PH-1049

This program applies to Commercial, Blue Partner, GenPlus, NetResults A series, SourceRx and Health Insurance Marketplace

POLICY REVIEW CYCLE

Effective Date	Date of Origin
07-01-2024

FDA LABELED INDICATIONS AND DOSAGE

See package insert for FDA prescribing information: https://dailymed.nlm.nih.gov/dailymed/index.cfm

POLICY AGENT SUMMARY QUANTITY LIMIT

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	QL Amount	Dose Form	Day Supply	Duration	Addtl QL Info	Allowed Exceptions	Targeted NDCs When Exclusions Exist

	zaleplon cap	10 MG ; 5 MG	30	Capsules	30	DAYS
	zolpidem tartrate cap	7.5 MG	30	Capsules	30	DAYS
	Zolpidem Tartrate SL Tab 1.75 MG	1.75 MG	30	Tablets	30	DAYS
	Zolpidem Tartrate SL Tab 3.5 MG	3.5 MG	30	Tablets	30	DAYS
Ambien	zolpidem tartrate tab	10 MG ; 5 MG	30	Tablets	30	DAYS
Ambien cr	zolpidem tartrate tab er	12.5 MG ; 6.25 MG	30	Tablets	30	DAYS
Belsomra	suvorexant tab	10 MG ; 15 MG ; 20 MG ; 5 MG	30	Tablets	30	DAYS
Dayvigo	lemborexant tab	10 MG ; 5 MG	30	Tablets	30	DAYS
Edluar	Zolpidem Tartrate SL Tab 10 MG	10 MG	30	Tablets	30	DAYS
Edluar	Zolpidem Tartrate SL Tab 5 MG	5 MG	30	Tablets	30	DAYS
Lunesta	eszopiclone tab	1 MG ; 2 MG ; 3 MG	30	Tablets	30	DAYS
Quviviq	daridorexant hcl tab	25 MG ; 50 MG	30	Tablets	30	DAYS
Rozerem	ramelteon tab	8 MG	30	Tablets	30	DAYS
Silenor	doxepin hcl (sleep) tab	3 MG ; 6 MG	30	Tablets	30	DAYS
Zolpimist	zolpidem tartrate oral spray	5 MG/ACT	1	Inhaler	30	DAYS

CLIENT SUMMARY – QUANTITY LIMITS

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
	zaleplon cap	10 MG ; 5 MG	Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx
	zolpidem tartrate cap	7.5 MG	Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx
	Zolpidem Tartrate SL Tab 1.75 MG	1.75 MG	Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx
	Zolpidem Tartrate SL Tab 3.5 MG	3.5 MG	Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx
Ambien	zolpidem tartrate tab	10 MG ; 5 MG	Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx
Ambien cr	zolpidem tartrate tab er	12.5 MG ; 6.25 MG	Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx
Belsomra	suvorexant tab	10 MG ; 15 MG ; 20 MG ; 5 MG	Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx
Dayvigo	lemborexant tab	10 MG ; 5 MG	Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx
Edluar	Zolpidem Tartrate SL Tab 10 MG	10 MG	Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx
Edluar	Zolpidem Tartrate SL Tab 5 MG	5 MG	Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx
Lunesta	eszopiclone tab	1 MG ; 2 MG ; 3 MG	Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx
Quviviq	daridorexant hcl tab	25 MG ; 50 MG	Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx
Rozerem	ramelteon tab	8 MG	Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx
Silenor	doxepin hcl (sleep) tab	3 MG ; 6 MG	Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx
Zolpimist	zolpidem tartrate oral spray	5 MG/ACT	Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx

QUANTITY LIMIT CLINICAL CRITERIA FOR APPROVAL

Module	Clinical Criteria for Approval
	Quantity Limit for the Target Agent(s) will be approved when ONE of the following is met: The requested quantity (dose) does NOT exceed the program quantity limit OR The requested quantity (dose) exceeds the program quantity limit AND ONE of the following: BOTH of the following: The requested agent does NOT have a maximum FDA labeled dose for the requested indication AND There is support for therapy with a higher dose for the requested indication OR BOTH of the following: The requested quantity (dose) does NOT exceed the maximum FDA labeled dose for the requested indication AND There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit OR BOTH of the following: The requested quantity (dose) exceeds the maximum FDA labeled dose for the requested indication AND There is support for therapy with a higher dose for the requested indication Length of Approval: up to 12 months

Module

Clinical Criteria for Approval

Quantity Limit for the Target Agent(s) will be approved when ONE of the following is met:

The requested quantity (dose) does NOT exceed the program quantity limit OR
The requested quantity (dose) exceeds the program quantity limit AND ONE of the following:
1. BOTH of the following:
  1. The requested agent does NOT have a maximum FDA labeled dose for the requested indication AND
  2. There is support for therapy with a higher dose for the requested indication OR
2. BOTH of the following:
  1. The requested quantity (dose) does NOT exceed the maximum FDA labeled dose for the requested indication AND
  2. There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit OR
3. BOTH of the following:
  1. The requested quantity (dose) exceeds the maximum FDA labeled dose for the requested indication AND
  2. There is support for therapy with a higher dose for the requested indication

Length of Approval: up to 12 months

This pharmacy policy is not an authorization, certification, explanation of benefits or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member’s plan in effect as of the date services are rendered. All pharmacy policies are based on (i) information in FDA approved package inserts (and black box warning, alerts, or other information disseminated by the FDA as applicable); (ii) research of current medical and pharmacy literature; and/or (iii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

The purpose of Blue Cross and Blue Shield of Alabama’s pharmacy policies are to provide a guide to coverage. Pharmacy policies are not intended to dictate to physicians how to practice medicine. Physicians should exercise their medical judgment in providing the care they feel is most appropriate for their patients.

Neither this policy, nor the successful adjudication of a pharmacy claim, is guarantee of payment.

Commercial _ PS _ Insomnia_Agents_QL _ProgSum_ 07-01-2024

Category Filter

Asset Publisher

Insomnia Agents Quantity Limit Program Summary

Policy Number: PH-1049

POLICY REVIEW CYCLE

CLIENT SUMMARY – QUANTITY LIMITS